Head

Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease

Retrieved on: 
Tuesday, April 9, 2024
FDA, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Development, Risk, Diabetes, Ageing, Chronic obstructive pulmonary disease, Head, RSV, Senior, Asthma, Safety, Vaccine, Person

Adults with certain underlying chronic conditions are at increased risk of developing, and being hospitalized for, RSV-associated LRTD1,2.

Key Points: 
  • Adults with certain underlying chronic conditions are at increased risk of developing, and being hospitalized for, RSV-associated LRTD1,2.
  • However, no RSV vaccines have been approved for use in adults 18 to 59 years of age.
  • The MONeT study was initiated to address this significant unmet need by investigating the immunogenicity and safety of ABRYSVO in adults aged 18 to 59 at increased risk for RSV disease, such as those with asthma, diabetes, and chronic obstructive pulmonary disease.
  • “These encouraging results provide evidence that ABRYSVO can help protect adults with increased risk against RSV-associated illness,” said Annaliesa Anderson, Ph.D., Senior Vice President and Head, Vaccine Research and Development, Pfizer.

Nvelop Therapeutics Launches with Dual Platforms for In Vivo Delivery of the Next Generation of Genetic Medicines

Retrieved on: 
Tuesday, April 9, 2024
Research, Medical Supplies, Infectious Diseases, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, Science, Culture, Broad Institute, Cell, Massachusetts General Hospital, Partner (business rank), Environment, Trust, RNP, MIT, Spark Therapeutics, Patient, Harvard University, Nature Biotechnology, Tissue, Head, Protein, Therapy, Former, Safety, Royal Naval Patrol Service, FDA, Management

Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today formally announced its launch to develop the next generation of genetic medicines for a wide range of diseases.

Key Points: 
  • Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today formally announced its launch to develop the next generation of genetic medicines for a wide range of diseases.
  • The company’s approach has the potential to enable highly efficient and cell-specific delivery of a broad set of therapeutic cargoes.
  • “The field of genetic medicine is significantly limited by the challenge of efficiently delivering therapeutic cargoes to many types of target cells in vivo,” said Jeff Walsh, Nvelop’s Chief Executive Officer.
  • In vivo data for the second platform is expected to be disclosed at one or more scientific meetings this year.

The Bliss Group’s Senior Leadership Team Expands to Meet Emerging Client and Talent Needs

Retrieved on: 
Tuesday, April 9, 2024
Public Relations, Investor Relations, Marketing, Content Marketing, Communications, Digital Marketing, Culture, Brandeis University, Data science, Executive, Financial services, Dartmouth College, Columbia University, Head, Life, Colgate University, Professional services, Content, Fortune 500, Management

JP Letourneau was promoted to Vice President in the Financial Services group.

Key Points: 
  • JP Letourneau was promoted to Vice President in the Financial Services group.
  • In September 2023, Adam Schwartzman was promoted to Group Vice President, Head of Content, and Ben Davis was promoted to Vice President in the Professional Services practice.
  • “Bliss is proud to recognize the smart and kind communications professionals who help our clients confront complicated issues with insights that bring change to life,” said Cortney Stapleton, CEO of The Bliss Group.
  • Her work as Head of Employee Experience will ensure the firm’s unique culture and reputation for developing strong talent remains a top priority.

Aeva Expands in Europe with New Automotive Center of Excellence in Germany

Retrieved on: 
Tuesday, April 9, 2024
Technology, General Automotive, Engineering, Robotics, Automotive Manufacturing, Manufacturing, Apps, Applications, Automotive, Vehicle Technology, Autonomous Driving, Vehicles, Other Technology, Software, Other Automotive, Hardware, Research, Original equipment manufacturer, ATG, COE, Perception, Head, Daimler Truck, Senior, Silicon, OEM, Torc Robotics, FMCW, Multimedia, Mercedes-Benz, Automotive industry

Aeva ® (NYSE: AEVA), a leader in next-generation sensing and perception systems, today announced that it is expanding its presence in Europe with a new Automotive Center of Excellence (COE) in Germany to support its growing momentum with automotive OEM customers.

Key Points: 
  • Aeva ® (NYSE: AEVA), a leader in next-generation sensing and perception systems, today announced that it is expanding its presence in Europe with a new Automotive Center of Excellence (COE) in Germany to support its growing momentum with automotive OEM customers.
  • Additionally, autonomous vehicle industry expert Axel Gern has joined the company as Head of Engineering in Germany and will lead the COE.
  • View the full release here: https://www.businesswire.com/news/home/20240409158765/en/
    The COE was created in response to growing interest from the automotive market in Aeva’s unique Frequency Modulated Continuous Wave (FMCW) technology.
  • “He will play a key role in building Aeva’s engineering team in Europe and leading our Automotive Center of Excellence as we ramp up to support our production win with Daimler Truck and support the growing interest and engagements with automotive customers globally.”

Peachtree Group Expands Executive Team with New Elevations

Retrieved on: 
Monday, April 8, 2024
Professional Services, Commercial Building & Real Estate, Lodging, Finance, Construction & Property, Travel, REIT, Mortgage Bankers Association, MBA, Eye, Multimedia, Knowledge, Head, Acquisition, Investment, Commercial property, Management

Peachtree Group ("Peachtree") announced the elevation of three senior executives, expanding their roles to strengthen the firm’s executive leadership team.

Key Points: 
  • Peachtree Group ("Peachtree") announced the elevation of three senior executives, expanding their roles to strengthen the firm’s executive leadership team.
  • The promotions include Michael Harper to president of hotel lending, Jared Schlosser to executive vice president of hotel lending and head of CPACE and Michael Ritz to executive vice president of investments.
  • View the full release here: https://www.businesswire.com/news/home/20240408928597/en/
    Peachtree Group ("Peachtree") announced the elevation of three senior executives, expanding their roles to strengthen the firm’s executive leadership team.
  • The promotions include Michael Harper (pictured) to president of hotel lending, Jared Schlosser to executive vice president of hotel lending and head of CPACE and Michael Ritz to executive vice president of investments.

Mythic Therapeutics Presents Preclinical Data on MYTX-011, an Investigational cMET-Targeting Antibody-Drug Conjugate (ADC), at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Therapy, Patient, Neoplasm, MMAE, AACR, ADC, Mouse, Head, Cancer, NSCLC, Medical imaging

Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, presented preclinical data from MYTX-011, its investigational cMET-targeting ADC, at the American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, presented preclinical data from MYTX-011, its investigational cMET-targeting ADC, at the American Association for Cancer Research (AACR) Annual Meeting.
  • “We previously demonstrated that MYTX-011 drives increased internalization and cytotoxicity in tumor cells expressing moderate cMET levels compared to a matched parent ADC in vitro.
  • MYTX-011 was shown to be highly active in cMET+ xenograft models derived from gastric, esophageal and head and neck cancers.
  • Together, these findings provide preclinical proof-of-concept of the potential of MYTX-011 as a therapeutic candidate for treating a broader range of cMET-expressing malignancies.

Movinglife Announces Major Expansion in the United States and Strategic Team Enhancements

Retrieved on: 
Tuesday, April 9, 2024
Travel, STAR, Head, Marketing, Food delivery

RICHMOND, Va., April 9, 2024 /PRNewswire/ - Movinglife , a pioneer in the development of innovative mobility solutions, including the ATTO folding mobility scooters,  announces a significant expansion of its operations within the United States.

Key Points: 
  • RICHMOND, Va., April 9, 2024 /PRNewswire/ - Movinglife , a pioneer in the development of innovative mobility solutions, including the ATTO folding mobility scooters,  announces a significant expansion of its operations within the United States.
  • Movinglife is integrating Folding Scooter Store, previously a premier dealer, into its corporate family as part of its growth strategy.
  • Movinglife's mobility experts offer home demos and/or phone assistance in states without a physical store, covering the entire United States.
  • Supporting this significant expansion, Movinglife appoints Hunter Donaldson as Head of US Operations and Ben Feldman , M.Med.Sc., as Global Chief Marketing Officer.

BON SECOURS MERCY HEALTH AND COMPASS SURGICAL PARTNERS ANNOUNCE GRAND OPENING OF WORLD-CLASS SURGERY CENTER IN GREENVILLE, SOUTH CAROLINA

Retrieved on: 
Tuesday, April 9, 2024
Elective surgery, Certification, Accreditation, Head, Organization, Abdominal ultrasonography, Surgeon, Partnership, Patient, MD, Quality of life, Sports medicine, ASC, Safety, Spine, Physician, Health, Neck, Bon, Hospital

GREENVILLE, S.C. and RALEIGH, N.C., April 9, 2024 /PRNewswire/ -- Millennium Surgery Center, a joint venture between Bon Secours Mercy Health, Compass Surgical Partners (Compass) and local physicians, today announced that it will launch in Greenville, South Carolina, with a grand opening on April 11.

Key Points: 
  • GREENVILLE, S.C. and RALEIGH, N.C., April 9, 2024 /PRNewswire/ -- Millennium Surgery Center, a joint venture between Bon Secours Mercy Health, Compass Surgical Partners (Compass) and local physicians, today announced that it will launch in Greenville, South Carolina, with a grand opening on April 11.
  • Located at 214 Innovation Drive in Greenville, South Carolina, the 20,000-square-foot facility will host a ribbon cutting ceremony on April 11 at 12pm.
  • Millennium Surgery Center expects to secure accreditation from the Accreditation Association for Ambulatory Health Care and certification from Medicare by mid-May.
  • The newly developed facility is the fourth opened thus far through the strategic partnership between Bon Secours Mercy Health and Compass.

Thought Leaders, Entrepreneurs and Active Investors Come Together to Shape Innovation at the 21st Annual What's Next Longevity Venture Summit

Retrieved on: 
Tuesday, April 9, 2024
Dark, Fairmont San Francisco, Head, Conference, MFA, Longevity, AARP, Government, Learning, Growth, Incubator, Running, AI, Investment banking, Ziegler, Housing, Summit, NIA, National Institute on Aging

LAFAYETTE, Calif., April 9, 2024 /PRNewswire/ -- Mary Furlong & Associates (MFA), producer of the longest running conference on the longevity economy, announced that the What's Next Longevity Venture Summit, will bring together thought leaders, including active investors, entrepreneurs, incubators, nonprofits, government agencies, providers and companies focused on the $9.5 trillion longevity market, June 11-12 at the Fairmont San Francisco. The theme, Net New: Investment, AI & Innovation In the Longevity Marketplace, will drive discussions on the key challenges and opportunities for those supporting the age 50+ market.

Key Points: 
  • The theme, Net New: Investment, AI & Innovation In the Longevity Marketplace, will drive discussions on the key challenges and opportunities for those supporting the age 50+ market.
  • "We put a laser focus on the active investors in the space today, highlighting the investment opportunities as well as forming partnerships for success in longevity.
  • And, to demonstrate their continued commitment to the Summit, the AgeTech Collaborative from AARP will be the title sponsor of this year's conference."
  • The What's Next Longevity Venture Summit will take place at the Fairmont San Francisco, June 11-12.

ERS electronic Announces Agreement with Geringer Halbleitertechnik GmbH & Co. KG to Strengthen R&D and Production Capabilities

Retrieved on: 
Tuesday, April 9, 2024
Small Business Saturday, Research, Head, Education minister, Retirement, ERS

MUNICH, April 9, 2024 /PRNewswire/ -- ERS electronic , the industry leader of thermal management solutions for semiconductor manufacturing has finalized an agreement with Geringer Halbleitertechnik GmbH & Co. KG , a move poised to bolster its research and development (R&D) and production capabilities.

Key Points: 
  • MUNICH, April 9, 2024 /PRNewswire/ -- ERS electronic , the industry leader of thermal management solutions for semiconductor manufacturing has finalized an agreement with Geringer Halbleitertechnik GmbH & Co. KG , a move poised to bolster its research and development (R&D) and production capabilities.
  • Geringer was founded in 1991 and has established itself as a reputable developer and manufacturer of tailor-made manufacturing machines for the semiconductor industry.
  • "We are thrilled to welcome the team from Geringer to ERS and expand our APEqS Business Unit," says Laurent Giai-Miniet, CEO of ERS electronic.
  • As I transition into retirement, I wish ERS all the best and am excited to see the great things they will accomplish."